297 related articles for article (PubMed ID: 17626183)
1. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.
Rottenberg S; Nygren AO; Pajic M; van Leeuwen FW; van der Heijden I; van de Wetering K; Liu X; de Visser KE; Gilhuijs KG; van Tellingen O; Schouten JP; Jonkers J; Borst P
Proc Natl Acad Sci U S A; 2007 Jul; 104(29):12117-22. PubMed ID: 17626183
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.
Zander SA; Kersbergen A; van der Burg E; de Water N; van Tellingen O; Gunnarsdottir S; Jaspers JE; Pajic M; Nygren AO; Jonkers J; Borst P; Rottenberg S
Cancer Res; 2010 Feb; 70(4):1700-10. PubMed ID: 20145144
[TBL] [Abstract][Full Text] [Related]
3. Lack of ABCG2 shortens latency of BRCA1-deficient mammary tumors and this is not affected by genistein or resveratrol.
Zander SA; Kersbergen A; Sol W; Gonggrijp M; van de Wetering K; Jonkers J; Borst P; Rottenberg S
Cancer Prev Res (Phila); 2012 Aug; 5(8):1053-60. PubMed ID: 22767648
[TBL] [Abstract][Full Text] [Related]
4. EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.
Zander SA; Sol W; Greenberger L; Zhang Y; van Tellingen O; Jonkers J; Borst P; Rottenberg S
PLoS One; 2012; 7(9):e45248. PubMed ID: 23028879
[TBL] [Abstract][Full Text] [Related]
5. What makes tumors multidrug resistant?
Borst P; Jonkers J; Rottenberg S
Cell Cycle; 2007 Nov; 6(22):2782-7. PubMed ID: 17998803
[TBL] [Abstract][Full Text] [Related]
6. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors.
Shafee N; Smith CR; Wei S; Kim Y; Mills GB; Hortobagyi GN; Stanbridge EJ; Lee EY
Cancer Res; 2008 May; 68(9):3243-50. PubMed ID: 18451150
[TBL] [Abstract][Full Text] [Related]
7. BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance.
Jaspers JE; Sol W; Kersbergen A; Schlicker A; Guyader C; Xu G; Wessels L; Borst P; Jonkers J; Rottenberg S
Cancer Res; 2015 Feb; 75(4):732-41. PubMed ID: 25511378
[TBL] [Abstract][Full Text] [Related]
8. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Rottenberg S; Jaspers JE; Kersbergen A; van der Burg E; Nygren AO; Zander SA; Derksen PW; de Bruin M; Zevenhoven J; Lau A; Boulter R; Cranston A; O'Connor MJ; Martin NM; Borst P; Jonkers J
Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17079-84. PubMed ID: 18971340
[TBL] [Abstract][Full Text] [Related]
9. Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo.
Pajic M; Kersbergen A; van Diepen F; Pfauth A; Jonkers J; Borst P; Rottenberg S
Cell Cycle; 2010 Sep; 9(18):3780-91. PubMed ID: 20855963
[TBL] [Abstract][Full Text] [Related]
10. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
11. Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.
Rottenberg S; Vollebergh MA; de Hoon B; de Ronde J; Schouten PC; Kersbergen A; Zander SA; Pajic M; Jaspers JE; Jonkers M; Lodén M; Sol W; van der Burg E; Wesseling J; Gillet JP; Gottesman MM; Gribnau J; Wessels L; Linn SC; Jonkers J; Borst P
Cancer Res; 2012 May; 72(9):2350-61. PubMed ID: 22396490
[TBL] [Abstract][Full Text] [Related]
12. Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance.
Hembruff SL; Laberge ML; Villeneuve DJ; Guo B; Veitch Z; Cecchetto M; Parissenti AM
BMC Cancer; 2008 Nov; 8():318. PubMed ID: 18980695
[TBL] [Abstract][Full Text] [Related]
13. [Expression of ABCG2 and p-glycoprotein in residual breast cancer tissue after chemotherapy and their correlation with epithelial-mesenchymal transition].
Qu H; Fang L; Duan L; Long X
Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):236-40. PubMed ID: 24915813
[TBL] [Abstract][Full Text] [Related]
14. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer.
Liu X; Holstege H; van der Gulden H; Treur-Mulder M; Zevenhoven J; Velds A; Kerkhoven RM; van Vliet MH; Wessels LF; Peterse JL; Berns A; Jonkers J
Proc Natl Acad Sci U S A; 2007 Jul; 104(29):12111-6. PubMed ID: 17626182
[TBL] [Abstract][Full Text] [Related]
15. ABCG2-meditated multidrug resistance and tumor-initiating capacity of side population cells from colon cancer.
Xie ZY; Lv K; Xiong Y; Guo WH
Oncol Res Treat; 2014; 37(11):666-8, 670-2. PubMed ID: 25427584
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas.
Hinoshita E; Uchiumi T; Taguchi K; Kinukawa N; Tsuneyoshi M; Maehara Y; Sugimachi K; Kuwano M
Clin Cancer Res; 2000 Jun; 6(6):2401-7. PubMed ID: 10873092
[TBL] [Abstract][Full Text] [Related]
17. Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway.
Wang Z; Yang L; Xia Y; Guo C; Kong L
Biol Pharm Bull; 2015; 38(2):277-84. PubMed ID: 25747987
[TBL] [Abstract][Full Text] [Related]
18. Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice.
Brodie SG; Xu X; Qiao W; Li WM; Cao L; Deng CX
Oncogene; 2001 Nov; 20(51):7514-23. PubMed ID: 11709723
[TBL] [Abstract][Full Text] [Related]
19. Increased levels of choline metabolites are an early marker of docetaxel treatment response in BRCA1-mutated mouse mammary tumors: an assessment by ex vivo proton magnetic resonance spectroscopy.
van Asten JJ; Vettukattil R; Buckle T; Rottenberg S; van Leeuwen F; Bathen TF; Heerschap A
J Transl Med; 2015 Apr; 13():114. PubMed ID: 25890200
[TBL] [Abstract][Full Text] [Related]
20. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
